Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
American Journal of Medical Genetics|February 5, 1998
Gene for topoisomerase III maps within the Smith-Magenis syndrome critical region: analysis of cell-cycle distribution and radiation sensitivityS H Elsea, E Fritz, R Schoener-Scott, et al.
Clinical Genetics|June 28, 2007
17p11.2p12 triplication and del(17)q11.2q12 in a severely affected child with dup(17)p11.2p12 syndromeS Girirajan, S R Williams, J Y Garbern, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 1992
Pharmacokinetic evaluation of two human epidermal growth factors (hEGF51 and hEGF53) in ratsB S Kuo, W F Kusmik, J C Poole, et al.
The Journal of Biological Chemistry|November 24, 1995
Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomeraseS J Froelich-Ammon, D A Burden, M W Patchan, et al.
American Journal of Medical Genetics|December 10, 1999
Hemizygosity for the COP9 signalosome subunit gene, SGN3, in the Smith-Magenis syndromeS H Elsea, K Mykytyn, K Ferrell, et al.
Clinical Genetics|June 2, 2007
Gender, genotype, and phenotype differences in Smith-Magenis syndrome: a meta-analysis of 105 casesE A Edelman, S Girirajan, B Finucane, et al.
American Journal of Human Genetics|May 1, 1996
Molecular analyses of 17p11.2 deletions in 62 Smith-Magenis syndrome patientsR C Juyal, L E Figuera, X Hauge, et al.
Pageof 3